Kyowa Kirin Co., Ltd., a prominent biopharmaceutical company, is headquartered in Tokyo, Japan (JP). Founded in 1949, the company has established a strong presence in the global healthcare industry, focusing on innovative drug development in areas such as oncology, nephrology, and immunology. Kyowa Kirin is renowned for its unique biologics and small molecule therapies, which leverage advanced technologies to address unmet medical needs. The company has achieved significant milestones, including the successful launch of several key products that have positioned it as a leader in the biopharmaceutical sector. With a commitment to research and development, Kyowa Kirin continues to expand its operational footprint across major regions, including North America, Europe, and Asia, solidifying its market position through strategic partnerships and a robust pipeline of therapeutic solutions.
How does Kyowa Kirin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Kyowa Kirin's score of 62 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Kyowa Kirin reported total carbon emissions of approximately 16133000 kg CO2e for Scope 1, 2087000 kg CO2e for Scope 2, and a significant 57473000 kg CO2e for Scope 3 emissions, which includes categories such as purchased goods and services (98054000 kg CO2e) and capital goods (57473000 kg CO2e). The total emissions from Scope 1 and 2 combined reached about 18221000 kg CO2e. Kyowa Kirin has set ambitious reduction targets, aiming for a 55% reduction in Scope 1 and Scope 2 emissions by 2030 compared to 2019 levels. This target is part of a broader commitment to reduce Scope 3 emissions by 30% within the same timeframe. Additionally, the company has committed to achieving net-zero greenhouse gas emissions across its entire value chain by 2050, as outlined in the Kirin Group Environmental Vision 2050. The company’s targets have been validated by the Science Based Targets initiative (SBTi), which confirms that their goals align with the necessary reductions to limit global warming to 1.5°C. Specifically, Kyowa Kirin aims to reduce Scope 1 and 2 emissions by 42% by 2030 from a 2021 baseline. Kyowa Kirin's emissions data is cascaded from its parent company, Kirin Holdings Company, Limited, reflecting a commitment to sustainability across its corporate family.
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 6,742,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 13,941,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Kyowa Kirin's Scope 3 emissions, which increased by 5% last year and increased by approximately 37% since 2022, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 60% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Kyowa Kirin has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.